News - Eliquis, Oncology

Filter

Current filters:

EliquisOncology

Popular Filters

1 to 25 of 1505 results

Potential to fast-track drugs in new Cancer Research UK partnership with AstraZeneca and Pfizer

Potential to fast-track drugs in new Cancer Research UK partnership with AstraZeneca and Pfizer

17-04-2014

British charity Cancer Research UK has joined forces with Anglo-Swedish drug major AstraZeneca and US…

AstraZenecaCancerHealthMajorMedicineOncologyPfizerPharmaceuticalPharmacologyResearchUK

EMA says that vials of falsified Herceptin have been identified

EMA says that vials of falsified Herceptin have been identified

16-04-2014

The European Medicines Agency says it has been informed that vials of Swiss drug major Roche’s blockbuster…

EuropeHealthcareHerceptinOncologyPharmaceuticalRegulationRoche

BioAlliance Pharma and Topotarget merge to create leader in orphan oncology diseases

BioAlliance Pharma and Topotarget merge to create leader in orphan oncology diseases

16-04-2014

French orphan drug developer BioAlliance Pharma and Denmark’s Topotarget today announced their intention…

belinostatBioAlliance PharmaLivatagMergers & AcquisitionsOncologyPharmaceuticalRare diseasesTopotarget

NeoStem to acquire California Stem Cell, expanding pipeline

14-04-2014

USA-based NeoStem has entered into a definitive agreement to acquire California Stem Cell, an Irvine,…

BiotechnologyCalifornia Stem Cellmelapuldencel-TMergers & AcquisitionsNeoStemOncologyResearch

Immune responses enhanced and sustained when Provenge is given after ADT in prostate cancer

Immune responses enhanced and sustained when Provenge is given after ADT in prostate cancer

12-04-2014

US biotech firm Dendreon has released positive preliminary data from a long-term analysis of the Phase…

BiotechnologyDendreonOncologyProvengeResearch

Chugai files NDA for vemurafenib for melanoma

Chugai files NDA for vemurafenib for melanoma

11-04-2014

Japanese drugmaker Chugai Pharmaceutical has filed a new drug application to the Ministry of Health,…

BRAFV600ChemistryChugai PharmaceuticalJapanJO28178OncologyOrganochloridesPharmaceuticalRegulationRoche Diagnosticsvemurafenib

Emerging therapies for relapsed/refractory CLL/SLL expected to offer efficacy benefits

Emerging therapies for relapsed/refractory CLL/SLL expected to offer efficacy benefits

11-04-2014

The effect of a therapy on overall survival and progression-free survival are attributes that most influence…

BiotechnologyEuropeGilead SciencesidelalisibImbruvicaJohnson & JohnsonMarkets & MarketingOncologyUSA

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

11-04-2014

The full year report from Anglo-Swedish drug major AstraZeneca (LSE: AZN) in February was full of optimism.…

AstraZenecaInterviewsIressaOncologyPharmaceuticalUK

Erytech adds a new product candidate to its development portfolio

10-04-2014

French cancer focused drug developer Erytech Pharma has added a new product development candidate, ERY-MET,…

ERY-METErytech PharmaOncologyPharmaceuticalResearch

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

09-04-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyGlaxoSmithKlineNorthern EuropeOncologyPharmaceuticalPricingRegulationTafinlarvemurafenib

FDA clinical hold on Halozyme’s PEGPH20 pancreatic cancer trial

FDA clinical hold on Halozyme’s PEGPH20 pancreatic cancer trial

09-04-2014

US biopharma firm Halozyme Therapeutics says that the US Food and Drug Administration informed the company…

Halozyme TherapeuticsNorth AmericaOncologyPharmaceuticalRegulationResearchUSA

Express Scripts forecasts unsustainable increases in specialty drug spend in USA

Express Scripts forecasts unsustainable increases in specialty drug spend in USA

09-04-2014

Expensive treatments for broad patient populations are driving unprecedented growth in US spending on…

Anti-Arthritics/RheumaticsAnti-viralsMarkets & MarketingNorth AmericaOncologyPharmaceuticalPricingUSA

Seattle Genetics earns $6 million milestone under Adcetris accord with Takeda

Seattle Genetics earns $6 million milestone under Adcetris accord with Takeda

08-04-2014

US biotech firm Seattle Genetics says it will receive milestone payments from Japan’s Takeda Pharmaceutical…

AdcetrisAsia-PacificBiotechnologyFinancialMarkets & MarketingOncologySeattle GeneticsSouth AmericaTakeda Pharmaceuticals

Pharmacyclics seeks additional indication for Imbruvica in USA

Pharmacyclics seeks additional indication for Imbruvica in USA

08-04-2014

USA-based Pharmacyclics has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug…

BiotechnologyImbruvicaJanssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmacyclicsRegulationUSA

Promising emerging agents for triple negative breast cancer

08-04-2014

Due to the heterogeneity of triple negative breast cancer, the most promising emerging agents in development…

Astellas PharmaBiotechnologyMarkets & MarketingMedivationniraparibOncologyTesaroXtandi

UK’s ValiRx forms joint venture to fast track lung cancer drug to Phase II

UK’s ValiRx forms joint venture to fast track lung cancer drug to Phase II

08-04-2014

UK biopharmaceutical company ValiRx has established ValiSeek, a joint venture company with Tangent Reprofiling.

Chief executiveLicensingLung cancerOncologyPharmaceuticalResearchScienceUKValiRxValiSeek

Pfizer palbociclib trial disappoints, despite meeting primary endpoint

Pfizer palbociclib trial disappoints, despite meeting primary endpoint

08-04-2014

At the American Association of Cancer Research (AACR) Annual Meeting 2014 in San Diego, US pharma giant…

AmgenOncologypalbociclibPfizerPharmaceuticalResearch

1 to 25 of 1505 results

Company Spotlight

Fibrotech

Fibrotech

Back to top